Ozurdex is a sustained release dexamethasone intravitreal implant that is approved for retinal vein occlusion, diabetic macular edema and posterior uveitis.
OZURDEX® (dexamethasone intravitreal implant) 0.7 mg is a biodegradable implant injected into the eye (vitreous) to treat adults with macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) and to treat adults with noninfectious uveitis affecting the back segment of the eye.
The OZURDEX® implant is so tiny that it can be injected into the eye (vitreous) with a procedure in your doctor's office. Each implant is already inside a special applicator device that is needed to perform the insertion. The implant will be injected into the vitreous humor inside your eye. This is known as an intravitreal injection.
Inside the eye, the implant is slowly dissolved by the vitreous gel that fills the eye, releasing medicine to reduce the swelling or inflammation. As the level of medication decreases over time, swelling or inflammation may affect your vision again. If this occurs, your doctor may recommend another OZURDEX® injection.
In 2 clinical studies, 427 patients were treated with OZURDEX® and 426 patients received sham (simulated) injections.
OZURDEX® intravitreal implant has been proven effective for noninfectious uveitis affecting the back segment of the eye in a clinical trial. OZURDEX® helps treat the inflammation causing vitreous haze that is affecting your vision. In a clinical study, 77 patients were treated with OZURDEX® and 76 patients received sham (simulated) injections.
Ozurdex was approved for treatment of diabetic macular edema in late 2014. Ozurdex is administered as an intravitreal injection.